JSR Life Sciences Launches 'Similis Bio' to Help Partners Accelerate Biosimilar Development
10.5.2022 15:00:00 EEST | Business Wire | Press release
JSR Life Sciences, LLC (JSR) today announced the launch of a new business division, Similis Bio (Similis), which will operate a partnering program designed to help biopharmaceutical companies improve the efficiency and cost of biosimilar development. Similis will rely on core expertise in developing and manufacturing biologics to mitigate the challenges inherent in biosimilar drug development.
Similis provides biosimilar drug developers with solutions designed to accelerate development timelines and lower costs. By offering complete analytical and process development packages, Similis supplies companies with data to determine an appropriate biosimilar target, accelerate early program development, and reduce analytical costs. Data packages include reference product data, analytical procedures, process expertise, and CMC templates from a centralized model designed to give partners access to higher quality biosimilar packages at a lower cost than other development models.
Additionally, Similis will establish co-development agreements with partner companies to start the development of multiple biosimilar programs in parallel, giving partners an exclusive right, but not an obligation, to purchase multiple programs. JSR designed this collaboration model to reduce the risk from program cancellations and extend market analysis timelines.
“This model will enable changes in strategy far beyond traditional drug development approaches by centralizing reference product data and expertise under one roof,” said JSR Life Sciences’ Chief Technology Officer Jean-Pierre Wery. “Similis brings the broad expertise of JSR Life Sciences companies together to jump-start the development of promising biosimilars. By improving timelines and development costs for drug makers, more biosimilars can be brought to market faster. Ultimately, that means more choice and lower costs for patients.”
Biosimilars—the generic form of FDA-approved biologics—are derived from living organisms, making them inherently complex. Unlike small-molecule generic drugs, biosimilars cannot fully replicate their brand-name counterparts, so an array of analytical data must be collected to ensure they sufficiently reflect biosimilarity to the FDA-approved reference products to which they are being compared. This process requires costly and significant investment in expertise, state-of-the-art technology, and extensive data gathering, including rigorous clinical trials to ensure a biosimilar's safety and efficacy. JSR launched Similis Bio to mitigate these barriers to market entry and promote more productive development programs.
For more information about Similis Bio visit: JSRLifeSciences.com/similis.
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005401/en/
Contact information
Missy Bindseil
JSR Life Sciences Company Inquiries
Director, Marketing & Communications
mbindseil@jsr-nahq.com
Mike Beyer
JSR Life Sciences Media Inquiries
Sam Brown Inc.
mikebeyer@sambrown.com
+1 312-961-2502
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Multi-Color Corporation Announces Recapitalization to Reset Balance Sheet and Position Company for Long-Term Growth and Investment27.1.2026 23:09:00 EET | Press release
Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced strategic actions to further position the Company for long-term growth and investment to best serve its customers. MCC has entered into a restructuring support agreement (the “RSA”) with holders of approximately 70% in amount of MCC’s secured first lien debt and its equity sponsor, CD&R, on the terms of a comprehensive financial restructuring. The transactions contemplated by the RSA will significantly deleverage MCC’s balance sheet, reducing its net debt load from approximately $5.9 billion to approximately $2.0 billion. The Company’s annualized cash interest will also be reduced from approximately $475 million to $140 million in 2026, a reduction of over $330 million, with long-term debt maturities extended to 2033 following consummation of the restructuring transactions. To implement the transactions contemplated by the RSA, MCC has launched a solicitation for votes in support
Logitech Announces Q3 Fiscal Year 2026 Results27.1.2026 23:05:00 EET | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the third quarter of Fiscal Year 2026. Sales were $1.42 billion, up 6 percent in US dollars and 4 percent in constant currency compared to Q3 of the prior year. GAAP gross margin was 43.2 percent, up 30 basis points compared to Q3 of the prior year. Non-GAAP gross margin was 43.5 percent, up 30 basis points compared to Q3 of the prior year. GAAP operating income was $286 million, up 22 percent compared to Q3 of the prior year. Non-GAAP operating income was $312 million, up 17 percent compared to Q3 of the prior year. GAAP earnings per share (EPS) was $1.69, up 28 percent compared to Q3 of the prior year. Non-GAAP EPS was $1.93, up 21 percent compared to Q3 of the prior year. Cash flow from operations was $481 million. The quarter-ending cash balance was $1.8 billion. “We delivered another quarter of excellent financial performance,” sai
Mobileum Launches GlobalRoamer® Connectivity Package for the FIFA World Cup 2026 to Assure Seamless Roaming and 5G Voice Performance Across North America27.1.2026 22:45:00 EET | Press release
Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, today announced a Special GlobalRoamer® package for the FIFA World Cup 2026, designed to help mobile network operators (MNOs) validate roaming readiness and maintain high-quality connectivity during one of the world’s most demanding network events, where service performance directly impacts roaming revenue, customer retention, and brand reputation. The FIFA World Cup 2026 will place unprecedented pressure on mobile networks across 16 stadiums in the United States, Canada, and Mexico, as millions of fans, teams, media, and officials rely on mobile services to stream, share, and communicate in real time. Sudden spikes in data, voice, and roaming traffic can degrade performance precisely when customer experience is most visible. Mobileum’s FIFA World Cup 2026 package builds on the GlobalRoamer® end-to-end active testing ecosystem used at major global events, including roaming quality campaigns conduc
Tacton Named a Leader in the 2026 Gartner® Magic Quadrant™ for CPQ Applications for the Fourth Consecutive Year27.1.2026 19:00:00 EET | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex, configurable products, today announced that it has been named a Leader in the 2026 Gartner® Magic Quadrant™ for CPQ Applications. This marks the fourth consecutive year Tacton has been recognized as a Leader in the report. Among the 16 vendors evaluated, Tacton placed highest in the quadrant on Completeness of Vision and for the second consecutive year is positioned highest in Ability to Execute. Tacton CPQ is designed to support manufacturers selling highly configurable products by helping them: Ensure accurate configuration so every quote reflects valid options and constraints Quote faster with confidence across high-variance portfolios without relying on manual engineering checks Maintain pricing and margin control through consistent configuration and pricing logic This approach supports manufacturers as they manage complexity while meeting buyer expectations for speed and accuracy. “We
CSG Recognized in Multi-Category Trusted Analyst Reports for CPQ, Monetization, and Digital Partner Management27.1.2026 18:05:00 EET | Press release
Communication service providers (CSPs) are under pressure to simplify complexity, monetize new services, and deliver experiences customers trust with speed and accuracy. To succeed, they need partners who can turn quote-to-cash and digital monetization into a competitive advantage, not just a back-office function. Over the past year, CSG® (NASDAQ: CSGS) has achieved multi-category recognition from leading analyst firms for doing exactly that. To CSG, these recognitions reinforce a role as a go-to partner for CSPs looking to move faster, unlock new revenue streams, and modernize their core with AI-powered, telco-specific platforms built for real-world complexity. CPQ Leadership for Complex B2B and B2B2X Monetization CSG Quote & Order continues to stand out for CSPs that need to configure complex offers, quote with confidence, and move from deal to revenue without friction. With Quote & Order, CSG is named: A Challenger in the 2026 Gartner® Magic Quadrant™ for Configure, Price & Quote Ap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom